ChEBI: A member of the class of benzamides that is N,N-dimethylbenzamide substituted by a formylamino group at position 4 and a [(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl group at position 2.
8 articles
SenesTech Inc. reported Q2 2026 financial results with revenue increasing 23% year-over-year to $770K, driven primarily by its Evolve product. Despite a net loss of $1.83M, gross margins improved to 7
SenesTech reported its active online subscription customer base doubled in Q2 2026, with e-commerce revenue surging 186% driven by digital marketing and sales channel management for its Evolve and Con
SenesTech reported its active online subscriptions more than doubled in Q2 2026, driving an 186% quarter-over-quarter e-commerce growth. This supports recurring revenue for its Evolve and ContraPest r
SenesTech Inc. reported $2.22 million USD total revenue last year, primarily driven by its 'Evolve' segment originating from the United States.
SenesTech reported Q1 2026 revenue of $493,000, a 2% year-over-year increase driven by Evolve products, despite net losses widening to $2.1 million due to higher operating expenses.
SenesTech reported record H1 2024 revenue driven by its Evolve rodent fertility control products, with Q2 revenue up 50% year-over-year. Management anticipates accelerated growth but notes additional
SenesTech reported a Q1 2026 net loss of $2.1 million despite revenue rising to $493,000, driven by Evolve fertility-control products accounting for 85% of sales. Improved margins support operations t
SenesTech reported a 2% year-over-year revenue increase to $493,000 for Q1 2026, driven by direct-to-consumer growth and a record 68.6% gross margin, while planning to expand its Evolve rodent control
ChemBrief